SCHEMBL3012857

SCHEMBL3012857

COc1ccc(OC)c(S(=O)(=O)N2CCN(c3nc(Cc4ccccc4)cs3)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
ALDH1A1 P00352 8/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
USP2 O75604 1/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
RECQL P46063 2/20 0.56
MAPT P10636 1/20 0.56
KDM4E B2RXH2 1/20 0.56
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PKM P14618 1/20 0.48
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3002250 0.94 ALDH1A1 (0.55) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3014122 0.94 ALDH1A1 (0.57) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3015761 0.93 ALDH1A1 (0.47) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3011303 0.92 ALDH1A1 (0.55) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3010974 0.92 ALDH1A1 (0.56) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3018772 0.92 ALDH1A1 (0.54) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3015304 0.91 ALDH1A1 (0.57) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3018100 0.91 ALDH1A1 (0.52) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3008781 0.91 ALDH1A1 (0.53) KMT2AALDH1A1L3MBTL1USP2LMNA
SCHEMBL3001250 0.90 ALDH1A1 (0.54) KMT2AALDH1A1L3MBTL1USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.